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Background. Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines,
breakthrough cases of Hib disease still affect a small proportion of vaccinated children in the United Kingdom.
We performed a retrospective study to compare the avidity of antibody directed against the Hib polysaccharide
capsule (PRP) in children who experienced Hib vaccine failure in the United Kingdom among 3 historical cohorts
and with age-matched healthy control subjects.
Methods. Serum samples from vaccinated children with invasive Hib disease were collected beginning in 1992
as part of enhanced surveillance for Hib disease following vaccine introduction. A total of 251 children who
experienced Hib vaccine failure were identified from 3 historical cohorts (1992–1995, 1996–1999, and 2000–2003).
The anti-PRP antibody concentration and avidity from healthy age-matched control subjects was obtained for the
3 contemporary time points (1995, 1999, and 2002). Serum anti-PRP antibody concentration was measured in
each of the samples using a standard Hib ELISA, and antibody avidity was determined using thiocyanate elution.
Results. Within the first 60 days after disease onset, there was no change in the anti-PRP antibody avidity,
and there was no statistically significant difference in the geometric mean Hib antibody avidity over the 3 study
periods. However, the children who experienced Hib vaccine failure had significantly lower Hib antibody avidity
than did healthy control subjects, despite a marked antibody response following infection.
Conclusions. Children who experience Hib disease despite vaccination appear to have a defect in immunological
priming, leading to a qualitative difference in Hib-specific memory B cells. Low anti-PRP antibody avidity decreases
the functional activity of anti-PRP antibody in the sera of these children experiencing vaccine failure, leading to
disease susceptibility.
The implementation of Haemophilus influenzae type b
(Hib) conjugate vaccine into routine vaccination sched-
ules has led to a 190% decrease in invasive Hib disease
[1, 2]. In the United Kingdom from 1992 through 1998,
the overall vaccine efficacy was estimated to be 98%,
and the disease incidence remained at a very low level
(0.65 cases per 100,000 children), with a 3-dose accel-
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erated primary vaccination schedule and no booster in
the second year of life [3]. Subsequently, an increase
in the number of cases was noted in 1999, and a rate
of 4.6 cases per 100,000 children was reported in 2002
[4]. This increase in the rate of invasive Hib disease
coincided with the distribution of a Hib combination
vaccine containing acellular pertussis with diphtheria
and tetanus (DTPa-Hib). Analysis of risk factors for
invasive Hib disease revealed a dose-dependent reduc-
tion in Hib antibody concentration in children receiv-
ing DTPa-Hib rather than the whole-cell pertussis vac-
cine that had been used previously [5]. Various other
factors may have contributed to the increase in cases,
but the resurgence of cases was controlled by offering
a booster dose of Hib vaccine in 2003 to all chil-
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dren aged !4 years. A booster in the second year of life was
introduced in 2006, to improve the persistence of population
immunity against Hib.
Coincident with the introduction of the Hib conjugate vac-
cine for all infants in the United Kingdom in 1992, with a
catch-up campaign for all children aged !4 years, active sur-
veillance was commenced to prospectively identify cases of Hib
vaccine failure. Because of the high vaccine efficacy achieved
and the excellent immunogenicity in healthy children [1, 6, 7]
and in those with chronic conditions (e.g., children with sickle
cell disease [8] or congenital asplenia [9] and children who
have received bone marrow transplants [10]), the rare occur-
rence of vaccine failure highlighted the presence of a subset of
the population with susceptibility to Hib disease despite vac-
cination. True vaccine failure (TVF) for Hib was defined as
invasive Hib disease occurring 12 weeks after receipt of a single
dose of Hib conjugate vaccine in a child aged 11 year or invasive
Hib disease occurring 11 week after receipt of at least 2 doses
of vaccine in a child aged !1 year.
One possible explanation for vaccine failure is that such cases
simply occur in children who, for technical reasons (e.g., poor
vaccine administration technique or poorly maintained vaccine
stock), were never adequately primed by their Hib vaccination
series. However, previous studies have clearly revealed an an-
amnestic antibody response following Hib disease in vaccinated
children [11, 12], indicating that the children had developed
disease despite immunological priming by the vaccine. Because
the antibody concentration before disease onset cannot be mea-
sured, it is not possible to determine whether the lack of a
protective level of antibody against the Hib polysaccharide cap-
sule (anti-PRP antibody) is the cause of Hib vaccine failure.
The serum anti-PRP antibody concentration decreases rapidly
after primary vaccination [4], and the absolute level does not
reflect the functional activity of the antibody [7, 11, 13]. How-
ever, anti-PRP antibody avidity correlates with bactericidal ac-
tivity [14] and immunological priming, even with low antibody
concentration [8, 15–17]. Thus, the functional activity of Hib
antibody after vaccination and the competence of priming
might be better reflected by evaluation of antibody avidity. In
this retrospective study, the avidity of anti-PRP antibody in
both healthy children and in children experiencing TVF in the
United Kingdom was investigated.
METHODS
Samples. Following Hib vaccine implementation in the UK
vaccination schedule in 1992, clinical information and serum
samples from children experiencing TVF were collected as part
of a national active surveillance study by the British Paediatric
Surveillance Unit in collaboration with the Health Protection
Agency Haemophilus Reference Unit and the Oxford Vaccine
Group. From 2000 onward, the study continued to be directed
by the latter 2 organizations. Selection of samples for inclusion
in this study is described in Results. Ethical approval for this
study was obtained from the Central Office for Research Ethics
Committee in Oxford, United Kingdom (REC: O4/Q1606/114).
Controls. The anti-PRP antibody concentration and avidity
level in serum samples from healthy UK children (aged 3–4
years), collected in 1995, 1999, and 2002 [18–20], were selected
as control values for the 3 historical cohorts (1992–1995, 1996–
1999, and 2000–2003, respectively). These children had received
3 doses of Hib conjugate vaccine as primary vaccination during
infancy and were enrolled in studies performed by the Oxford
Vaccine Group. The blood samples were obtained 3–4 years
after primary vaccination, and a single serum sample was avail-
able for each child. Ethical approval for the use of the samples
was obtained from the Oxfordshire’s Research Ethics Com-
mittee (OXREC number: C02.013).
ELISA assay. Because of the difficulty in interpreting his-
torical data obtained using different methods, the anti-PRP
antibody concentration of all samples was remeasured using
the standard Hib ELISA protocol [21]. The anti-PRP antibody
avidity was then determined using a thiocyanate elution assay,
as described elsewhere [22]. The antibody avidity, the relative
strength of antibody binding to the antigen, was displayed as
the avidity index (AI) corresponding to the molar concentra-
tion of thiocyanate required to produce a 50% reduction in
optical density. The antibody response to tetanus toxoid and
its avidity were also measured using a tetanus ELISA protocol
and a thiocyanate elution assay, as describe elsewhere [23, 24].
Statistical analysis. Both antibody and avidity data were
log-transformed before analysis. Comparisons of the 3 histor-
ical cohorts were determined using regression analysis, with
and without adjustment for possible confounding factors, such
as age and the interval between disease onset and day of sample
collection. Comparison between the case data and control data
was also performed using regression analysis, with adjustment
for age and historical cohorts. The relative difference between
the 2 cohorts was calculated by the exponent of the coefficient
obtained from the regression model. All analyses were per-
formed using Stata, version 9.2 (Stata).
RESULTS
Sample selection. Serum samples from a total of 251 children
who experienced TVF were identified (figure 1). Of these sub-
jects, 48 were excluded, either because of transcriptional errors
in subject information or because of a delay in sample collection
of 160 days after admission to the hospital for Hib disease.
Sixty subjects were excluded because of medical conditions that
might affect their immune response, such as prematurity, Down
syndrome, malignancy, or immunodeficiency. The remaining
143 subjects were categorized into 3 historical cohorts as fol-
lows: 1992–1995 (the period after vaccine introduction, when
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Figure 1. The process of sample selection for this study. Hib, Hae-
mophilus influenzae type b; TVF, true vaccine failure.
Figure 2. The variation of avidity levels of antibody against Hae-
mophilus influenzae type b polysaccharide capsule (anti-PRP antibody) in
relation to the time between the first and second sample collection
( ) after hospital admission for invasive Haemophilus influenzaenp 37
type b disease.
the prevalence of invasive Hib disease was decreasing), 1996–
1999 (a period of low Hib disease prevalence), and 2001–2003
(a period with a marked increase in Hib disease prevalence).
Children who experienced TVF and had multiple serum
samples obtained. There were 37 individuals with 2 samples
of sufficient volume for analysis that had been collected during
the first 60 days after the onset of Hib disease. The first serum
samples were collected at 4 days after disease onset (range, 0–
15 days), and the second samples were collected at 31 days
after disease onset (range, 8–59 days). The serum AI in the
same individuals revealed no systematic difference between the
2 separate samples over the first 60 days after disease onset
(figure 2).
Antibody concentration and avidity in serum samples from
children who experienced TVF. The anti-PRP antibody con-
centration was measured for all available serum samples
( ; figure 3). Antibody avidity could be measured innp 143
serum samples from 108 individuals. For the remaining sam-
ples, there was either insufficient serum volume available or
the antibody concentration was too low for avidity measure-
ment (!0.3 mg/mL). Antibody concentration correlated closely
with the levels previously recorded using routine assays for each
individual at the time of disease (data not shown). The children
in the 3 cohorts had comparable age distribution (although
there were more younger children in the later cohort) (figure
1). The median durations from disease onset to the day of
sample collection for the 3 cohorts (1992–1995, 1996–1999,
and 2001–2003) were 8 days (range, 0–57 days), 6 days (range,
0–50 days), and 12 days (range, 0–51 days), respectively. There
was marginal evidence of statistical significance of anti-PRP
antibody among the 3 cohorts ( and , beforePp .04 Pp .07
and after adjustment for confounding factors, respectively) (fig-
ure 3 and table 1). In particular, the mean antibody concen-
tration in the 1996–1999 cohort was 4-fold higher than the
mean antibody concentration in the 1992–1995 cohort (table
1). There was no evidence of difference observed in antibody
avidity among the 3 groups (figure 4).
Comparison of serum samples from children who experi-
enced TVF with serum samples from healthy control subjects.
Because of the discrepancy in age distribution between the
patients with Hib disease and healthy control subjects, only
samples from patients who experienced TVF who were 13 years
of age at the time of sampling (42 children) were selected for
initial comparison (avidity analysis was possible for 33 of these
samples). As shown in figure 5, the antibody level in the samples
from children who experienced TVF was significantly higher
than that in the samples from control subjects ( ), withP ! .001
geometric mean concentrations of 4.46 mg/mL and 0.29 mg/
mL, respectively. However, the AI of the samples from children
who experienced TVF was significantly lower than that of sam-
ples from control subjects ( , figure 5), with a geometricP ! .001
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Figure 3. Concentration of antibody against Haemophilus influenzae type b polysaccharide capsule (anti-PRP antibody) in serum samples from children
who experienced true vaccine failure across 3 historical cohorts. The dots represent the geometric mean value, and the lines represent 95% CIs.
Table 1. Comparison of the relative difference in antibody con-
centration among 3 cohorts of patients who experienced true
vaccine failure, with and without adjustment, using the 1992–1995











1996–1999 4.05 (1.36–12.08) .01 3.69 (1.19–11.4) .02
2000–2003 1.67 (0.59–4.69) .6 2.12 (0.71–6.34) .2
a Adjusted for age at hospital admission and interval between disease onset
and day of sample collection.
mean AI of 0.12 and 0.24, respectively. This outcome remained
statistically significant, even when all case patients ( ;np 143
geometric mean antibody concentration, 3.66 mg/mL; geomet-
ric mean avidity index, 0.10) were considered for analysis, com-
pared with all control subjects ( ). There was no statis-P ! .001
tically significant difference in either the antitetanus antibody
concentration or avidity between the children who experienced
TVF and healthy control subjects (data not shown).
DISCUSSION
This large study provides compelling evidence that the occur-
rence of Hib disease in vaccinated children may be related to
the failure of normal immunological priming, leading to im-
pairment of avidity maturation of Hib-specific B cells or lack
or loss of B cells producing high-avidity antibody, despite evi-
dence that priming has permitted significant antibody responses
to be achieved following invasive Hib disease. The antibody
concentration was higher in the serum samples from children
who experienced TVF than in samples from the healthy age-
matched control subjects, even at the earliest time points after
disease onset, indicating an anamnestic response after the ex-
posure to Hib [11]. However, the low AI in the children who
experienced TVF suggests an intrinsic defect in anti-PRP an-
tibody avidity maturation, which increased their susceptibility
to disease. In support of this, in a series involving 12 children
who experienced TVF in The Netherlands, Breukels et al. [13]
also found lower serum antibody avidity. The low avidity does
not appear to reflect a general defect in production of high-
avidity antibody, because we found no difference in avidity to
tetanus toxoid between the children who experienced TVF and
control subjects.
In accordance with our findings, Breukels et al. [13] docu-
mented no significant changes in the avidity index of samples
from children who experienced TVF at disease onset and during
the convalescent phase (3–4 weeks after disease onset). Simi-
larly, the AI does not change during the month after a booster
dose of Hib vaccine in healthy children [17], indicating that
the serum AI of children who experience TVF is likely to reflect
their immune status prior to Hib disease. Thus, low levels of
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Figure 4. Avidity of antibody against Haemophilus influenzae type b polysaccharide capsule (anti-PRP antibody) in serum samples from children
who experienced true vaccine failure across 3 historical cohorts. The dots represent the geometric mean value, and the lines represent 95% CIs. For
both comparisons, , after adjustment for age and historical cohorts.P ! .001
Figure 5. Comparison of the concentration (A) and avidity (B) of antibody against Haemophilus influenzae type b polysaccharide capsule (anti-PRP
antibody) in serum samples from children who experienced true vaccine failure (case patients) and in samples from healthy control subjects (control
group) during the period 1992–2003.
functional antibody may provide the explanation for their dis-
ease susceptibility.
The lower Hib antibody concentration in the 1992–1995
cohort in our study may reflect the high levels of herd immunity
at the time of the Hib vaccine catch-up campaign in 1992 and
low rates of natural boosting by nasopharyngeal carriage of the
organism. AIs were low in all 3 cohorts of patients who ex-
perienced TVF from the early 1990s through 2003, despite dif-
ferences in population immunity and disease epidemiology
during these periods. Previous studies have suggested that many
of the cases of TVF in the 2001–2003 cohort may have been
associated with deleterious effects on Hib immunogenicity
caused by interaction with acellular pertussis in a combined
DTPa-Hib vaccine [5, 15, 25–27]. We have previously found
that use of this combined DTPa-Hib vaccine was associated
with lower Hib antibody avidity in healthy children. Because
the avidity of Hib antibody in the general population appears
to have been lower during 2001–2003 as a result of this inter-
action, the observed increase in cases during this period may
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reflect an avidity-related increase in population susceptibility,
further supporting our observations.
We were concerned that handling of the serum samples may
have varied among the samples obtained since 1992. However,
the lack of change in avidity among the 3 cohorts and the
similar tetanus avidity between case samples and control sam-
ples do not indicate any significant effects of sample storage
on the Hib analysis.
This study provides strong evidence suggesting that defective
priming leads to a reduction in either the number or the quality
of memory B cells induced by immunization or a loss of avidity
in matured B cells prior to disease onset. The lack of high-
avidity anti-PRP antibody results in susceptibility to Hib dis-
ease. Pichichero et al. [17] studied a group of children who
initially had low anti-PRP antibody concentrations and AIs,
despite 3-dose priming with Hib vaccine, who showed a larger
increase in antibody avidity following a booster, compared with
other children. Earlier studies also confirmed that children who
experience TVF respond to an additional dose of conjugate
vaccine [12, 13]. These observations indicate that the problem
may have been related to the vaccine (loss of vaccine epitopes
through inadequate handling or storage or uncoupling of con-
jugation affecting immunogenicity), rather than to a specific
defect in the infant’s ability to have a normal immune response,
or that these children had a maturational defect in their re-
sponse to this conjugate vaccine that later recovered. In either
instance, the defective maturation of antibody avidity might be
overcome with an additional dose of Hib conjugate vaccine,
providing support for introduction of a booster dose of Hib
vaccine for all children in the second year of life, as was finally
commenced in the United Kingdom in Autumn 2006.
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